Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Ad.p53-DC vaccine + Indoximod |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ad.p53-DC vaccine | INGN-225 | p53 Vaccine 5 | INGN-225 (Ad.p53-DC vaccine) is an adenoviral-p53 dendritic cell vaccine, which potentially induces a cytotoxic immune response against tumor cells over expressing Tp53 (PMID: 20420527). | |
Indoximod | D-1MT|1-MT|NLG-8189 | IDO1 Inhibitor 12 | Indoximod (D-1MT) inhibits indoleamine 2,3-dioxygenase 1 (IDO1), which decreases metabolism of tryptophan to kynurenine, potentially resulting in increased T-cell proliferation and activation and enhanced anti-tumor immune response (PMID: 17234791, PMID: 32637034, PMID: 34117113). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01042535 | Phase Ib/II | Ad.p53-DC vaccine + Indoximod | Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer | Completed | USA | 0 |